🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT04217044
Recruiting Observational

Histopathology Images Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence

NCT04217044 · tracked via the Priya Life Science China tracker
Sponsor
The First Affiliated Hospital of Zhengzhou University
Phase
Observational
Started
2017-01-01
Last updated
2021-02-08

Condition(s) studied

Glioma

Investigational drug(s) / intervention(s)

Histopathology images based prediction of molecular pathology

Histopathology images based prediction of molecular pathology: Histopathology images based prediction of 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations or molecular subgroups by leveraging AI

Study summary

This registry aims to collect clinical, molecular and radiologic data including detailed clinical parameters, molecular pathology (1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations, etc) and images of HE slices in primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine histopathology image based algorithms that are able to predict molecular pathology or subgroups of gliomas.

Eligibility

Sex
ALL
Min age
1 Year
Max age
95 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Patients must have radiologically and histologically confirmed diagnosis of primary glioma * Life expectancy of greater than 3 months * Must receive tumor resection * Signed informed consent Exclusion Criteria: * No gliomas * No sufficient amount of tumor tissues for detection of molecular pathology * Patients who are pregnant or breast feeding * Patients who are suffered from severe systematic malfunctions

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University Zhengzhou Henan Recruiting

More The First Affiliated Hospital of Zhengzhou University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04217044 on ClinicalTrials.gov ↗ ← All trials in China